Targovax Selected for Oral Presentation at Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting

Corporate Breaking News

Home : Targovax Selected for Oral Presentation at Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting

Oct 09 2019	Targovax Selected for Oral Presentation at Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting
OSLO, Norway, Oct. 9, 2019 /PRNewswire/ -- Targovax ASA (OSE: TRVX), announces that clinical data on the company's lead product candidate ONCOS-102, a genetically modified oncolytic adenovirus which has been engineered to selectively infect and replicate in cancer cells, will be presented...


Source:https://www.prnewswire.com:443/news-releases/targovax-selected-for-oral-presentation-at-society-for-immunotherapy-of-cancer-sitc-2019-annual-meeting-300934520.html

Related News
» AbbVie Announces New Data from its Dermatology Portfolio and Pipeline at the 28th European Academy of Dermatology and Venereology (EADV) Congress » KEMA Laboratories to Change Ownership From DNV GL to CESI